Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection

Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection

The recent COVID-19 pandemic is a treatment challenge in the acute infection stage but the recognition of chronic COVID-19 symptoms termed post-acute sequelae SARS-CoV-2 infection (PASC) may affect up to 30% of all infected individuals. The underlying mechanism and source of this distinct immunologi...

Full description

Bibliographic Details
Main Authors: Bruce K. Patterson, Edgar B. Francisco, Ram Yogendra, Emily Long, Amruta Pise, Hallison Rodrigues, Eric Hall, Monica Herrera, Purvi Parikh, Jose Guevara-Coto, Timothy J. Triche, Paul Scott, Saboor Hekmati, Dennis Maglinte, Xaiolan Chang, Rodrigo A. Mora-Rodríguez, Javier Mora
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Immunology
Subjects:
COVID-19
PASC
SARS CoV-2 S1 protein
non-classical monocytes
CCR5
fractalkine
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.746021/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.746021/full

Similar Items